Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sciclone pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Maven1 who wrote (1125)	7/30/2006 10:35:35 PM
From: Skywatcher	Respond to of 1137

I guess there's always hope....very little at this point

To: Maven1 who wrote (1125)	10/31/2006 2:55:01 PM
From: Skywatcher	Respond to of 1137

SciClone's Outlook Gets Better By Althea Chang TheStreet.com Staff Reporter 10/31/2006 11:35 AM EST Click here for more stories by Althea Chang Drug developer SciClone Pharmaceuticals (SCLN - commentary - Cramer's Take) reported better-than-expected third-quarter results and boosted its revenue guidance for the year, sending shares higher Tuesday. The company reported a loss of $1.3 million, or 3 cents a share, compared with a loss of $3.1 million, or 7 cents a share, in the third quarter a year ago. Analysts expected the company to lose 5 cents. Revenue came in at $8.3 million for the quarter, up from $7.2 million a year ago. Wall Street was looking for revenue of around $8.1 million. Shares of SciClone were up 5.7% to $2.41. Sales of SciClone's lead product Zadaxin advanced 18% to $8.27 million thanks to gains in China, which accounts for more than 90% of the overall revenue for the hepatitis C treatment. "In the months ahead, we plan to expand our clinical and regulatory abilities and are intensifying our business development efforts to in-license product candidates for China," said Dr. Friedhelm Blobel, president and CEO of SciClone. Looking ahead, the company expects to exceed its previous 2006 revenue guidance of $32 million and post a profit for the year.

To: Maven1 who wrote (1125)	11/20/2006 12:21:32 PM
From: Skywatcher	Respond to of 1137

Alfred Rudolph, M.D. Is Leaving as Chief Operating Officer Monday November 20, 6:30 am ET SAN MATEO, CA--(MARKET WIRE)--Nov 20, 2006 -- SciClone Pharmaceuticals (NASDAQ:SCLN - News) today announced that Alfred Rudolph, M.D., Chief Operating Officer, is leaving the Company, effective November 17, 2006. The Company is actively working to identify a successor. In the interim, Friedhelm Blobel, Ph.D., President and Chief Executive Officer, will assume the duties and functions of the position. ADVERTISEMENT Dr. Rudolph joined SciClone in 1997 to head the clinical, research, regulatory, manufacturing, and quality assurance functions of the Company. In 1998, he was appointed Chief Operating Officer. During his tenure in that office, SciClone expanded its registration approvals for the sale of its lead product ZADAXIN to dozens of countries, and conducted, by itself and with its European marketing partner Sigma-Tau, late stage clinical programs for ZADAXIN treatment of hepatitis C, malignant melanoma, and hepatocellular carcinoma. "I am very positive about SciClone's prospects and current capabilities," stated Dr. Rudolph. "My years at SciClone, the organization we have built, and what we have achieved together have been professionally rewarding for me," he added. "We are appreciative and thankful for Al's many contributions to SciClone," commented Dr. Blobel. "Al's guidance and leadership of his team members has been an important factor in the creation of the opportunities in SciClone's future."

To: Maven1 who wrote (1125)	12/22/2006 1:01:33 PM
From: Skywatcher	Respond to of 1137

Today is THE DAY finally SciClone says melanoma trial showed positive survival data LONDON (MarketWatch) -- SciClone Pharmaceuticals Inc. (SCLN : SciClone Pharmaceuticals Inc News , chart, profile, more Last: 3.27+1.01+44.79% 3.27, +1.01, +44.8%) and Sigma-Tau said that a large phase 2 trial treating patients with stage IV malignant melanoma, showed positive interim survival data. Data from the first four arms of this ongoing five-arm trial showed that the addition of 3.2 mg of ZADAXIN to standard dacarbazine chemotherapy increased the median survival to 10.2 months, the companies said.